tesamorelin vs retatrutide comparison and are two of the most widely studied names in the peptide space — and together, their dual focus on body composition and metabolic activity is turning heads in ongoing AOD-9604 vs MOTS-c vs Tesamorelin

10.4 Ocular delivery barriers and potential side effects The bloodretinal barrier, composed of tight junctions in retinal vascular endothelial cells and the RPE, hinders the penetration of macromolecular drugs (such as iron chelators) into the posterior segment of the eye (181)

Starting dose: 2.5 mg weekly (for 4 weeks) Titrated up in 2.5 mg increments every 4 weeks Common maintenance doses: 10 mg to 15 mg weekly Maximum studied dose: 15 mg weekly This slow escalation is designed to improve tolerance while still achieving substantial reductions in body weight and HbA1c

Weeks 1 through 4 begin at 1mg once weekly

Hypoglycemia and insulin adjustments: GLP-1 RAs alone carry low hypoglycemia risk